A Phase II, Multicenter, Single-Arm, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of Triple Therapy with Dolutegravir plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects - Not applicable

Blueclinical, Ltd.0 个研究点目标入组 30 人开始时间: 2016年12月5日最近更新: 2022年3月2日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Able to understand and willing to comply with all the requirements of the study, as confirmed by giving voluntary written informed consent for participation.
•2. Male or female gender.
•3. Age = 18 years on the day of signing the informed consent.
•4. HIV-2 positive as determined by a positive result in the respective assay.
•5. CD4 count =500 cells/mm3 (in case of undetectable baseline HIV-2 viral load);
•and/or classified as B- or C-stage, by the HIV disease staging and classification system of Centers for Disease Control and Prevention (CDC); and/or have detectable viral load irrespective of CD4 count; and/or have other medical conditions / co-morbidities in which treatment is considered, according to European AIDS Clinical Society (EACS) and national guidelines.
•6. Naïve to ART including investigational antiretroviral agents1.
•7. Considered clinically stable with no signs or symptoms of active infection, at the time of entry into the study (i.e., clinical status and all chronic medications should be unchanged for at least 2 weeks prior to the start of treatment in this study), in the opinion of the investigator.
•8. If woman or man with reproductive potential, agrees to adopt one of the following effective contraceptive methods throughout the study:
•a) True abstinence, if this is in line with the preferred and usual lifestyle of the subject [Period abstinence (e.g., abstinence only on certain calendar days, abstinence only during ovulation period, use of symptothermal method, use of post-ovulation methods) and withdrawal are not acceptable methods of contraception].
•b) Use of an acceptable method of birth control throughout the study (either by subject or subject’s partner) from 30 days prior to the first dose of the study medication and until the last dose of study medication and completion of the Follow-up visit. The acceptable methods of birth control in this study are:
•- Abstinence of heterosexual intercourse (when this is in line with preferred and usual lifestyle of the subject).
•- Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable).
•- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal).
•- Intrauterine device (IUD), if approved by the Investigator.
•- Intrauterine hormone-releasing system.
•- Bilateral tubal occlusion.
•- Vasectomized partner, who has received medical assessment of the surgical success.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 25
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

排除标准

•1. History or presence of allergy to the study drugs or their components.
•2. HIV-1 infection or HIV-1/HIV-2 dual infection.
•3. History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject’s participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
•4. Documented or known resistance to DTG and/or NRTIs.
•5. Treatment with systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study.
•NOTE: Short courses of corticosteroids (e.g., as for asthma exacerbation) will be allowed. Short courses” mean a use of corticosteroids for less than 7 days.
•6. Requiring or is anticipated to require any of the prohibited medications while in the study (dofetilide, inducers of CYP3A4, including phenobarbital, phenytoin, carbamazepine and rifampicin).
•NOTE: Subjects must discontinue phenobarbital, phenytoin, carbamazepine, and rifampicin at least 14 days prior to the treatment phase of the study.
•7. Current (active) diagnosis of tuberculosis.
•8. Alanine aminotransferase (ALT) =5 times the upper limit of normal (ULN), or ALT =3xULN and bilirubin =1.5xULN (with >35% direct bilirubin).
•9. Moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification3.
•10. If subject eligible to receive Tivicay®: Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
•11. Estimated creatinine clearance <50 mL/min at time of screening, based on Cockcroft-Gault equation4.
•12. Current (active) diagnosis of acute hepatitis due to any cause.
•NOTE: Subjects with chronic hepatitis B and C may enter the study as long as they fulfil all entry criteria, have stable liver function tests, and have no significant impairment of hepatic synthetic function (significant impairment of hepatic synthetic function is defined as a serum albumin <2.8 g/dL in the absence of another explanation for the abnormal laboratory value) at the time of enrollment.
•13. Under treatment for a viral infection other than HIV-2, such as hepatitis B, with an agent that may be active against HIV-2, including but not limited to 3TC, TDF or entecavir, unless the treatment with these agents occurred prior to the diagnosis of HIV.
•14. Anticipated need for Hepatitis C virus (HCV) therapy with interferon and/or ribavirin during the study.
•15. Positive HLA-B*5701 allele screening assessment and is also not eligible for treatment with the other acceptable NRTIs (TDF/FTC).
•16. Significant suicidality risk, according to the investigator’s judgment.
•NOTE: Recent history of suicidal behavior and/or suicidal ideation may be considered as evidence of serious suicide risk.
•17. Participation in a study with an investigational compound/device within 30 days of signing informed consent or anticipates participating in such a study involving an investigational compound/device during the course of this study.
•18. If woman, she is pregnant, breastfeeding, or expecting to conceive at any time during the study.
•19. If woman, she is expecting to donate eggs at any time during the study.
•20. If man, expecting to d

研究者

发起方

Blueclinical, Ltd.

相似试验

进行中（未招募）

1 期

Study to evaluate the efficacy of INCMGA00012 in patients with penile cancernresectable locally advanced or metastatic penile squamous cell carcinoma (PSqCC).MedDRA version: 20.0Level: PTClassification code 10034299Term: Penile cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-001172-11-ESMedica Scientia Innovation Research (MedSIR)15

招募中

1 期

EUCTR2019-001172-11-ITMEDICA SCIENTIA INNOVATION RESEARCH, ARO18

进行中（未招募）

1 期

A multicenter, open-label, single-arm, phase II trial exploring the maintenance of trastuzumab and pertuzumab following trastuzumab deruxtecan as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer patients.

CTIS2023-507306-13-00Medica Scientia Innovation Research S.L.132

进行中（未招募）

不适用

A phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the safety and Efficacy of Single-Agent Lenalidomide Revlimid in Subjects with Relapsed or Refractory Aggressive Non-Hodgkin s Lymphoma - ND

EUCTR2006-004500-40-ITCELGENE EUROPE LIMITED128

进行中（未招募）

1 期

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and AboveInfluenza

EUCTR2013-000545-39-BEovartis Vaccines and Diagnostics S.r.l.